EP1687018A4 - Inhibitoren des hepatitis-c-virus - Google Patents

Inhibitoren des hepatitis-c-virus

Info

Publication number: EP1687018A4
Authority: EP; European Patent Office
Prior art keywords: sub; hepatitis; virus inhibitors; compounds; disclosed
Prior art date: 2003-11-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP04811049A

Other languages

English (en)

French (fr)

Other versions

EP1687018A1 (de

EP1687018B1 (de

Inventor

Paul Michael Scola

Fiona Mcphee

Nicholas A Meanwell

Piyasena Hewawasam

Jeffrey Allen Campbell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-12

Filing date

2004-11-12

Publication date

2008-04-02

2004-11-12 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2006-08-09 Publication of EP1687018A1 publication Critical patent/EP1687018A1/de

2008-04-02 Publication of EP1687018A4 publication Critical patent/EP1687018A4/de

2012-01-25 Application granted granted Critical

2012-01-25 Publication of EP1687018B1 publication Critical patent/EP1687018B1/de

2024-11-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EP04811049A 2003-11-12 2004-11-12 Inhibitoren des hepatitis-c-virus Expired - Lifetime EP1687018B1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51912403P	2003-11-12	2003-11-12
PCT/US2004/038165 WO2005046712A1 (en)	2003-11-12	2004-11-12	Hepatitis c virus inhibitors

Publications (3)

Publication Number	Publication Date
EP1687018A1 EP1687018A1 (de)	2006-08-09
EP1687018A4 true EP1687018A4 (de)	2008-04-02
EP1687018B1 EP1687018B1 (de)	2012-01-25

Family

ID=34590359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04811049A Expired - Lifetime EP1687018B1 (de)	2003-11-12	2004-11-12	Inhibitoren des hepatitis-c-virus

Country Status (8)

Country	Link
US (1)	US7132504B2 (de)
EP (1)	EP1687018B1 (de)
JP (1)	JP4675331B2 (de)
AT (1)	ATE542826T1 (de)
ES (1)	ES2380934T3 (de)
IS (1)	IS8448A (de)
NO (1)	NO20062267L (de)
WO (1)	WO2005046712A1 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ335276A (en)	1996-10-18	2000-09-29	Vertex Pharma	Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
US7176208B2 (en)	2003-04-18	2007-02-13	Enanta Pharmaceuticals, Inc.	Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
PE20050204A1 (es) *	2003-05-21	2005-05-04	Boehringer Ingelheim Int	Compuestos inhibidores de la hepatitis c
PE20050374A1 (es)	2003-09-05	2005-05-30	Vertex Pharma	Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
MXPA06003141A (es)	2003-09-22	2006-06-05	Boehringer Ingelheim Int	Peptidos macrociclicos activos contra el virus de la hepatitis c.
US7491794B2 (en) *	2003-10-14	2009-02-17	Intermune, Inc.	Macrocyclic compounds as inhibitors of viral replication
US7132504B2 (en)	2003-11-12	2006-11-07	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7309708B2 (en)	2003-11-20	2007-12-18	Birstol-Myers Squibb Company	Hepatitis C virus inhibitors
US7135462B2 (en)	2003-11-20	2006-11-14	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2549851C (en)	2004-01-21	2012-09-11	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis c virus
JP4914348B2 (ja) *	2004-06-28	2012-04-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎インヒビターペプチド類似体
JP4914355B2 (ja) *	2004-07-20	2012-04-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es) *	2004-07-20	2006-02-24	Boehringer Ingelheim Int	Analogos de dipeptidos inhibidores de la hepatitis c
MX2007003812A (es)	2004-10-01	2007-05-24	Vertex Pharma	Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc).
MY141025A (en)	2004-10-29	2010-02-25	Vertex Pharma	Dose forms
US7323447B2 (en)	2005-02-08	2008-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP4705164B2 (ja)	2005-05-02	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7592336B2 (en)	2005-05-10	2009-09-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
KR101510065B1 (ko)	2005-06-08	2015-04-07	다나-파버 캔서 인스티튜트 인크.	예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
US7601686B2 (en)	2005-07-11	2009-10-13	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TWI389908B (zh) *	2005-07-14	2013-03-21	Gilead Sciences Inc	抗病毒化合物類
CA2615921C (en) *	2005-07-20	2011-09-13	Boehringer Ingelheim International Gmbh	Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety
CN101263156A (zh) *	2005-07-25	2008-09-10	因特蒙公司	C型肝炎病毒复制的新颖大环抑制剂
MX2008001588A (es)	2005-08-01	2008-02-19	Merck & Co Inc	Inhibidores de proteasa ns3 del vhc.
JP5015154B2 (ja)	2005-08-12	2012-08-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ウイルスポリメラーゼインヒビター
AR055395A1 (es)	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en)	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
NZ568135A (en)	2005-10-11	2011-06-30	Array Biopharma Inc	Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en)	2005-10-12	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7741281B2 (en)	2005-11-03	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7816348B2 (en)	2006-02-03	2010-10-19	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
CN101489557B (zh)	2006-02-27	2013-12-18	弗特克斯药品有限公司	包含vx-950的共晶体和包含所述共晶体的药物组合物
NZ571280A (en)	2006-03-16	2011-10-28	Vertex Pharma	Deuterated hepatitis C protease inhibitors
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
US7728148B2 (en) *	2006-06-06	2010-06-01	Enanta Pharmaceuticals, Inc.	Acyclic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) *	2006-06-06	2008-08-07	Ying Sun	Acyclic oximyl hepatitis c protease inhibitors
GB0612423D0 (en)	2006-06-23	2006-08-02	Angeletti P Ist Richerche Bio	Therapeutic agents
AR061629A1 (es) *	2006-06-26	2008-09-10	Enanta Pharm Inc	Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
KR20090024834A (ko)	2006-07-05	2009-03-09	인터뮨, 인크.	Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008008776A2 (en)	2006-07-11	2008-01-17	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
BRPI0714343A2 (pt)	2006-07-13	2013-03-19	Achillion Pharmaceuticals Inc	peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral
US20090035267A1 (en) *	2007-07-31	2009-02-05	Moore Joel D	Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7635683B2 (en) *	2006-08-04	2009-12-22	Enanta Pharmaceuticals, Inc.	Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7687459B2 (en) *	2006-08-11	2010-03-30	Enanta Pharmaceuticals, Inc.	Arylalkoxyl hepatitis C virus protease inhibitors
US20080038225A1 (en) *	2006-08-11	2008-02-14	Ying Sun	Triazolyl acyclic hepatitis c serine protease inhibitors
EP1886685A1 (de)	2006-08-11	2008-02-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
CN101506167A (zh)	2006-08-17	2009-08-12	贝林格尔.英格海姆国际有限公司	病毒聚合酶抑制剂
CA2667146C (en)	2006-10-24	2016-01-19	Merck & Co., Inc.	Hcv ns3 protease inhibitors
US8377873B2 (en)	2006-10-24	2013-02-19	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
US8309540B2 (en)	2006-10-24	2012-11-13	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
BRPI0718161A2 (pt)	2006-10-27	2013-11-26	Merck & Co Inc	Composto, composição farmacêutica, e, uso do composto.
JP5352464B2 (ja)	2006-10-27	2013-11-27	メルク・シャープ・アンド・ドーム・コーポレーション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
US8343477B2 (en)	2006-11-01	2013-01-01	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7772180B2 (en)	2006-11-09	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7763584B2 (en)	2006-11-16	2010-07-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7888464B2 (en)	2006-11-16	2011-02-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8003604B2 (en)	2006-11-16	2011-08-23	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
GB0625349D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
WO2008075103A1 (en)	2006-12-20	2008-06-26	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Antiviral indoles
GB0625345D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
US8435984B2 (en)	2007-02-26	2013-05-07	Achillion Pharmaceuticals, Inc.	Tertiary amine substituted peptides useful as inhibitors of HCV replication
EA200970806A1 (ru)	2007-02-27	2010-08-30	Вертекс Фармасьютикалз Инкорпорейтед	Сокристаллы и содержащие их фармацевтические композиции
JP2010519329A (ja)	2007-02-27	2010-06-03	バーテックスファーマシューティカルズインコーポレイテッド	セリンプロテアーゼ阻害剤
PT2144604E (pt)	2007-02-28	2011-10-19	Conatus Pharmaceuticals Inc	Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
US20080267917A1 (en) *	2007-04-26	2008-10-30	Deqiang Niu	N-functionalized amides as hepatitis c serine protease inhibitors
KR20100027134A (ko) *	2007-05-10	2010-03-10	인터뮨, 인크.	Ｃ형 간염 바이러스 복제의 신규 펩티드 억제제
US20090005387A1 (en) *	2007-06-26	2009-01-01	Deqiang Niu	Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
JP5465667B2 (ja)	2007-06-29	2014-04-09	ギリアードサイエンシーズ，インコーポレイテッド	抗ウイルス化合物
EA019749B1 (ru)	2007-06-29	2014-06-30	Джилид Сайэнс, Инк.	Противовирусные соединения
JP2010533698A (ja)	2007-07-17	2010-10-28	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー	Ｃ型肝炎感染症の治療のための大環状インドール誘導体
JP5433573B2 (ja)	2007-07-19	2014-03-05	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ	抗ウイルス剤としての大環状化合物
WO2009018657A1 (en)	2007-08-03	2009-02-12	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
EP2185546B1 (de) *	2007-08-30	2011-10-26	Vertex Pharmceuticals Incorporated	Kokristalle und pharmazeutische zusammensetzungen damit
CA2700383A1 (en)	2007-09-24	2009-04-02	Achillion Pharmaceuticals, Inc.	Urea-containing peptides as inhibitors of viral replication
US8263549B2 (en) *	2007-11-29	2012-09-11	Enanta Pharmaceuticals, Inc.	C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
WO2009070689A1 (en) *	2007-11-29	2009-06-04	Enanta Pharmaceuticals, Inc.	Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
WO2009076166A2 (en) *	2007-12-05	2009-06-18	Enanta Pharmaceuticals, Inc.	Oximyl hcv serine protease inhibitors
WO2009076173A2 (en)	2007-12-05	2009-06-18	Enanta Pharmaceuticals, Inc.	Fluorinated tripeptide hcv serine protease inhibitors
NZ585370A (en)	2007-12-19	2012-09-28	Boehringer Ingelheim Int	Viral polymerase inhibitors
NZ586232A (en)	2007-12-21	2012-12-21	Avila Therapeutics Inc	HCV protease inhibitors comprising a functionalised proline derivative
US8309685B2 (en)	2007-12-21	2012-11-13	Celgene Avilomics Research, Inc.	HCV protease inhibitors and uses thereof
US8293705B2 (en)	2007-12-21	2012-10-23	Avila Therapeutics, Inc.	HCV protease inhibitors and uses thereof
US8202996B2 (en)	2007-12-21	2012-06-19	Bristol-Myers Squibb Company	Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
BRPI0821559A2 (pt) *	2007-12-21	2015-06-16	Avila Therapeutics Inc	Produto de confeitaria congelado
CN101980719A (zh) *	2008-01-24	2011-02-23	益安药业	含杂芳基的三肽hcv丝氨酸蛋白酶抑制剂
CN102036966A (zh) *	2008-01-24	2011-04-27	益安药业	作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
KR100945784B1 (ko)	2008-01-24	2010-03-08	한국외국어대학교 연구산학협력단	Ｃ형 간염 바이러스의 중합효소 ｎｓ５ｂ를 저해하는 c형 간염 바이러스 치료제
RU2490272C2 (ru)	2008-02-04	2013-08-20	Айденикс Фармасьютикалз, Инк.	Макроциклические ингибиторы серинпротеазы
CN102015652A (zh) *	2008-03-20	2011-04-13	益安药业	作为丙型肝炎病毒抑制剂的氟化大环化合物
CA2720729A1 (en)	2008-04-15	2009-11-26	Intermune, Inc.	Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en)	2008-04-16	2012-04-24	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8461107B2 (en)	2008-04-28	2013-06-11	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
US8211891B2 (en) *	2008-04-30	2012-07-03	Enanta Pharmaceuticals, Inc.	Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
US7964560B2 (en)	2008-05-29	2011-06-21	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2009148923A1 (en)	2008-05-29	2009-12-10	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
RS53420B (sr)	2008-07-22	2014-12-31	Msd Italia S.R.L.	Kombinacije makrocikličnog jedinjenja hinoksalina koje je inhibitor hcv ns3 proteaze sa drugim hcv sredstvima
US8207341B2 (en)	2008-09-04	2012-06-26	Bristol-Myers Squibb Company	Process or synthesizing substituted isoquinolines
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en)	2008-09-29	2011-10-25	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8563505B2 (en)	2008-09-29	2013-10-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2009319701B2 (en)	2008-11-28	2014-10-09	Dana-Farber Cancer Institute, Inc.	Methods for the treatment of infections and tumors
SI2364309T1 (sl)	2008-12-10	2015-03-31	Achillion Pharmaceuticals, Inc.	Novi 4-amino-4-oksobutanoil peptidi kot inhibitorji virusne replikacije
US8283310B2 (en)	2008-12-15	2012-10-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201034663A (en)	2008-12-19	2010-10-01	Gilead Sciences Inc	HCV NS3 protease inhibitors
SG172848A1 (en)	2009-01-07	2011-08-29	Scynexis Inc	Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2010093843A2 (en)	2009-02-12	2010-08-19	Vertex Pharmaceuticals Incorporated	Hcv combination therapies
AR075584A1 (es)	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
TW201040181A (en)	2009-04-08	2010-11-16	Idenix Pharmaceuticals Inc	Macrocyclic serine protease inhibitors
MX2011012155A (es)	2009-05-13	2012-02-28	Enanta Pharm Inc	Compuestos macrociclicos como inhibidores del virus de hepatitis c.
US8232246B2 (en)	2009-06-30	2012-07-31	Abbott Laboratories	Anti-viral compounds
WO2011014487A1 (en)	2009-07-30	2011-02-03	Merck Sharp & Dohme Corp.	Hepatitis c virus ns3 protease inhibitors
US9284307B2 (en)	2009-08-05	2016-03-15	Idenix Pharmaceuticals Llc	Macrocyclic serine protease inhibitors
US9193740B2 (en) *	2009-10-19	2015-11-24	Enanta Pharmaceuticals, Inc.	Bismacrocyclic compounds as hepatitis C virus inhibitors
RU2012136824A (ru)	2010-01-29	2014-03-10	Вертекс Фармасьютикалз Инкорпорейтед	Способы лечения вирусной инфекции гепатита с
WO2011156545A1 (en)	2010-06-09	2011-12-15	Vertex Pharmaceuticals Incorporated	Viral dynamic model for hcv combination therapy
TW201208704A (en)	2010-07-14	2012-03-01	Vertex Pharma	Palatable pharmaceutical composition
UA116616C2 (uk)	2010-09-21	2018-04-25	Енанта Фармасьютікалз, Інк.	Інгібітори hcv серинової протеази, отримані з макроциклічного проліну
EA201390532A1 (ru) *	2010-10-08	2013-09-30	Новартис Аг	Композиции сульфамидых ингибиторов ns3, содержащие витамин е
MX2013007698A (es)	2010-12-30	2013-08-15	Abbvie Inc	Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
MX2013007677A (es)	2010-12-30	2013-07-30	Abbvie Inc	Inhibidores macrociclicos de serina proteasa de hepatitis.
AR085352A1 (es)	2011-02-10	2013-09-25	Idenix Pharmaceuticals Inc	Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012109646A1 (en)	2011-02-11	2012-08-16	Vertex Pharmaceuticals Incorporated	Treatment of hcv in hiv infection patients
WO2012107589A1 (en)	2011-02-11	2012-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8691757B2 (en)	2011-06-15	2014-04-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9328138B2 (en)	2011-11-15	2016-05-03	Msd Italia S.R.L.	HCV NS3 protease inhibitors
WO2013116339A1 (en)	2012-01-31	2013-08-08	Vertex Pharmaceuticals Incorporated	High potency formulations of vx-950
BR112015007879A2 (pt)	2012-10-19	2017-07-04	Bristol Myers Squibb Co	inibidores do vírus da hepatite c
WO2014071007A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2014070964A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
EP2914614B1 (de)	2012-11-05	2017-08-16	Bristol-Myers Squibb Company	Inhibitoren des hepatitis-c-virus
JP6342922B2 (ja)	2013-03-07	2018-06-13	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｃ型肝炎ウイルス阻害剤
WO2014152928A2 (en)	2013-03-14	2014-09-25	Achillion Pharmaceuticals, Inc.	Novel processes for producing sovaprevir
US9006423B2 (en)	2013-03-15	2015-04-14	Achillion Pharmaceuticals Inc.	Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
BR112015023351A2 (pt)	2013-03-15	2017-07-18	Achillion Pharmaceuticals Inc	forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
WO2014145600A1 (en)	2013-03-15	2014-09-18	Achillion Pharmaceuticals, Inc.	Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004094452A2 (en) *	2003-04-16	2004-11-04	Bristol-Myers Squibb Company	Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
WO2005028501A1 (en) *	2003-09-22	2005-03-31	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis c virus

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5610054A (en)	1992-05-14	1997-03-11	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecule targeted against Hepatitis C virus
MY147327A (en)	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
GB9517022D0 (en)	1995-08-19	1995-10-25	Glaxo Group Ltd	Medicaments
US5633388A (en)	1996-03-29	1997-05-27	Viropharma Incorporated	Compounds, compositions and methods for treatment of hepatitis C
WO1997043310A1 (en)	1996-05-10	1997-11-20	Schering Corporation	Synthetic inhibitors of hepatitis c virus ns3 protease
NZ335276A (en)	1996-10-18	2000-09-29	Vertex Pharma	Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
AU7127298A (en)	1997-04-14	1998-11-11	Emory University	Serine protease inhibitors
GB9707659D0 (en)	1997-04-16	1997-06-04	Peptide Therapeutics Ltd	Hepatitis C NS3 Protease inhibitors
AU757072B2 (en)	1997-08-11	2003-01-30	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C inhibitor peptide analogues
JP4354632B2 (ja)	1997-08-11	2009-10-28	ベーリンガーインゲルハイム（カナダ）リミテッド	Ｃ型肝炎抑制剤ペプチド
IT1299134B1 (it)	1998-02-02	2000-02-29	Angeletti P Ist Richerche Bio	Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
DK1066247T3 (da)	1998-03-31	2007-04-02	Vertex Pharma	Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
GB9812523D0 (en)	1998-06-10	1998-08-05	Angeletti P Ist Richerche Bio	Peptide inhibitors of hepatitis c virus ns3 protease
WO2000006529A1 (en)	1998-07-27	2000-02-10	Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A.	Diketoacid-derivatives as inhibitors of polymerases
AR022061A1 (es)	1998-08-10	2002-09-04	Boehringer Ingelheim Ca Ltd	Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
BR9913157A (pt)	1998-08-21	2001-05-15	Viropharma Inc	Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
WO2000013708A1 (en)	1998-09-04	2000-03-16	Viropharma Incorporated	Methods for treating or preventing viral infections and associated diseases
AU751457B2 (en)	1998-09-25	2002-08-15	Viropharma Incorporated	Methods for treating or preventing viral infections and associated diseases
UA74546C2 (en)	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
EP1225899A2 (de)	1999-11-04	2002-07-31	Virochem Pharma Inc.	Methode zur behandlung und vorbeugung von flaviviridae viralinfekten mit nukleosidanalogen
CA2363274A1 (en)	1999-12-27	2001-07-05	Japan Tobacco Inc.	Fused-ring compounds and use thereof as drugs for hepatitis c
JP2004509066A (ja)	2000-05-10	2004-03-25	スミスクライン・ビーチャム・コーポレイション	新規抗感染症薬
US6448281B1 (en)	2000-07-06	2002-09-10	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
GB0017676D0 (en)	2000-07-19	2000-09-06	Angeletti P Ist Richerche Bio	Inhibitors of viral polymerase
PE20020707A1 (es)	2000-11-20	2002-08-11	Bristol Myers Squibb Co	Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
DE60314595T2 (de) *	2002-01-24	2008-03-06	Japan Science And Technology Agency, Kawaguchi	Nichtlineare widerstandsschaltung mit floating-gate-mosfets
CA2369711A1 (en)	2002-01-30	2003-07-30	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en)	2002-02-01	2003-08-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor tri-peptides
CA2370396A1 (en)	2002-02-01	2003-08-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor tri-peptides
US6642204B2 (en)	2002-02-01	2003-11-04	Boehringer Ingelheim International Gmbh	Hepatitis C inhibitor tri-peptides
US6828301B2 (en)	2002-02-07	2004-12-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
JP4312718B2 (ja)	2002-05-20	2009-08-12	ブリストル−マイヤーズスクイブカンパニー	Ｃ型肝炎ウイルス阻害剤
AU2003248535A1 (en)	2002-05-20	2003-12-12	Bristol-Myers Squibb Company	Heterocyclicsulfonamide hepatitis c virus inhibitors
PL213029B1 (pl)	2002-05-20	2012-12-31	Bristol Myers Squibb Co	Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
WO2004101605A1 (en) *	2003-03-05	2004-11-25	Boehringer Ingelheim International Gmbh	Hepatitis c inhibiting compounds
PE20050204A1 (es) *	2003-05-21	2005-05-04	Boehringer Ingelheim Int	Compuestos inhibidores de la hepatitis c
US7132504B2 (en)	2003-11-12	2006-11-07	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors

2004
- 2004-11-10 US US10/985,106 patent/US7132504B2/en not_active Expired - Lifetime
- 2004-11-12 AT AT04811049T patent/ATE542826T1/de active
- 2004-11-12 ES ES04811049T patent/ES2380934T3/es not_active Expired - Lifetime
- 2004-11-12 WO PCT/US2004/038165 patent/WO2005046712A1/en not_active Ceased
- 2004-11-12 EP EP04811049A patent/EP1687018B1/de not_active Expired - Lifetime
- 2004-11-12 JP JP2006539980A patent/JP4675331B2/ja not_active Expired - Fee Related
2006
- 2006-05-10 IS IS8448A patent/IS8448A/is unknown
- 2006-05-19 NO NO20062267A patent/NO20062267L/no not_active Application Discontinuation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004094452A2 (en) *	2003-04-16	2004-11-04	Bristol-Myers Squibb Company	Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
WO2005028501A1 (en) *	2003-09-22	2005-03-31	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis c virus

Also Published As

Publication number	Publication date
US20050187165A1 (en)	2005-08-25
US7132504B2 (en)	2006-11-07
ES2380934T3 (es)	2012-05-21
JP2007534636A (ja)	2007-11-29
ATE542826T1 (de)	2012-02-15
WO2005046712A1 (en)	2005-05-26
EP1687018A1 (de)	2006-08-09
JP4675331B2 (ja)	2011-04-20
IS8448A (is)	2006-05-10
EP1687018B1 (de)	2012-01-25
NO20062267L (no)	2006-08-04

Publication	Publication Date	Title
EP1687018A4 (de)	2008-04-02	Inhibitoren des hepatitis-c-virus
MY140680A (en)	2010-01-15	Hepatitis c virus inhibitors
WO2005054430A3 (en)	2005-09-15	Hepatitis c virus inhibitors
WO2004094452A3 (en)	2005-05-19	Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
NO20062339L (no)	2006-08-10	Hepatitt C virus-inhibitoerer
WO2008057875A3 (en)	2008-07-31	Inhibitors of hepatitis c virus
WO2008057873A3 (en)	2008-10-09	Inhibitors of hepatitis c virus
WO2004014852A3 (en)	2004-04-22	Iminothiazolidinones as inhibitors of hcv replication
MX2009004888A (es)	2009-05-19	Inhibidores del virus de la hepatitis c.
IL198741A0 (en)	2010-02-17	Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof
WO2006122188A3 (en)	2007-03-08	Tripeptides as hepatitis c virus inhibitors
TW200745120A (en)	2007-12-16	Indolobenzazepine HCV NS5B inhibitors
WO2008008776A3 (en)	2008-04-03	Hepatitis c virus inhibitors
GEP20094751B (en)	2009-08-10	Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
UA83046C2 (ru)	2008-06-10	Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
WO2004062613A3 (en)	2004-11-04	Hiv integrase inhibitors
WO2001074768A3 (en)	2002-06-06	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AP1771A (en)	2007-08-23	3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
WO2002048116A3 (en)	2007-10-25	Inhibitors of hepatitis c virus ns3 protease
NO20091704L (no)	2009-07-27	Inhibitorer av hepatitt C virus
TW200615275A (en)	2006-05-16	Hepatitis C inhibitor dipeptide analogs
WO2007092888A3 (en)	2007-10-11	Hcv ns5b inhibitors
WO2007008657A3 (en)	2007-05-31	Hepatitis c virus inhibitors
WO2008021927A3 (en)	2008-05-29	Hepatitis c virus inhibitors
GB0011071D0 (en)	2000-06-28	Organic compounds

Legal Events

Date	Code	Title	Description
2006-07-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-08-09	17P	Request for examination filed	Effective date: 20060504
2006-08-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR
2006-08-09	AX	Request for extension of the european patent	Extension state: AL HR LT LV MK YU
2007-03-30	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1094429 Country of ref document: HK
2008-04-02	A4	Supplementary search report drawn up and despatched	Effective date: 20080303
2008-04-02	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/06 20060101ALI20080226BHEP Ipc: C07K 5/08 20060101AFI20080226BHEP
2009-02-25	17Q	First examination report despatched	Effective date: 20090126
2011-06-24	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2011-11-15	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2011-12-23	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2012-01-25	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR
2012-01-25	AX	Request for extension of the european patent	Extension state: AL HR LT LV MK YU
2012-01-25	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2012-01-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2012-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 542826 Country of ref document: AT Kind code of ref document: T Effective date: 20120215
2012-02-29	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2012-03-22	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602004036320 Country of ref document: DE Effective date: 20120322
2012-05-16	REG	Reference to a national code	Ref country code: NL Ref legal event code: VDEP Effective date: 20120125
2012-05-21	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2380934 Country of ref document: ES Kind code of ref document: T3 Effective date: 20120521
2012-06-25	LTLA	Lt: lapse of european patent or patent extension
2012-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120525 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125
2012-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120525 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120426 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125
2012-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 542826 Country of ref document: AT Kind code of ref document: T Effective date: 20120125
2012-09-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125
2012-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125
2012-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125
2012-11-30	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2012-11-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2013-01-02	26N	No opposition filed	Effective date: 20121026
2013-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125
2013-02-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602004036320 Country of ref document: DE Effective date: 20121026
2013-06-07	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1094429 Country of ref document: HK
2013-06-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2013-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121130
2013-08-14	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2013-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121112
2014-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20131106 Year of fee payment: 10 Ref country code: FR Payment date: 20131108 Year of fee payment: 10
2014-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120125 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121130
2014-05-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121112
2014-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20041112
2015-01-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20141013 Year of fee payment: 11 Ref country code: DE Payment date: 20141105 Year of fee payment: 11
2015-03-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20141117 Year of fee payment: 11
2015-07-29	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20141112
2015-08-28	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20150731
2015-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141112
2015-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141201
2016-06-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602004036320 Country of ref document: DE
2016-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151112
2016-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160601
2016-12-27	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20161227
2017-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151113